Ex­clu­sive: Texas biotech rais­es $47M to move heart surgery drug in­to piv­otal study

Renibus means kid­ney in Latin, but Renibus Ther­a­peu­tics is go­ing for the heart first.

The South­lake, TX-based biotech raised a $47 mil­lion Se­ries B to help car­ry a drug that may re­duce the risk of com­pli­ca­tions in heart surgery in­to a Phase III tri­al. The goal of the treat­ment is two-fold: cut the risk of surgery for pa­tients, and in do­ing so, re­duce the time and cost of hos­pi­tal stays.

The $47 mil­lion came pri­mar­i­ly from “lead­ers in the car­diac surgery com­mu­ni­ty” and fam­i­ly of­fices — an “in­sid­er-led round,” co-CEO Frank Stonebanks told End­points News, though he de­clined to com­ment on who those in­di­vid­u­als were.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER